Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Angiomax bivalirudin: Pilot data; marketed in New Zealand; under FDA and EMEA review

Baylor College of Medicine researchers presented data from 60 patients undergoing coronary

Read the full 124 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE